| scholarly article | Q13442814 |
| P2093 | author name string | Matthew Glass | |
| Chiou-Miin Wang | |||
| Paul T Martin | |||
| Marybeth Camboni | |||
| Sarah Devries | |||
| P2860 | cites work | Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 |
| Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch | Q24676179 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease | Q28269894 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function | Q29614851 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display | Q30988173 | ||
| Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease | Q33943122 | ||
| Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice | Q34025748 | ||
| Reduced levels of amyloid beta-peptide antibody in Alzheimer disease | Q34090874 | ||
| Towards a network theory of the immune system. | Q34202813 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| Mimotope vaccines: epitope mimics induce anti-cancer antibodies | Q34655015 | ||
| Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice | Q48521871 | ||
| Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins | Q48601563 | ||
| Autoantibodies to amyloid-beta and Alzheimer's disease | Q48839422 | ||
| Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. | Q51811574 | ||
| Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. | Q52264322 | ||
| Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. | Q53238194 | ||
| Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study | Q53295392 | ||
| Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals | Q74372174 | ||
| Immunotherapy for Alzheimer's disease | Q80129880 | ||
| Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology | Q34763076 | ||
| Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease | Q35169132 | ||
| Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice | Q35834451 | ||
| Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage | Q35844472 | ||
| Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss | Q35918370 | ||
| A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease | Q36565633 | ||
| Mice as models: transgenic approaches and Alzheimer's disease. | Q36568096 | ||
| Lymphokine control of in vivo immunoglobulin isotype selection. | Q36576188 | ||
| The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein | Q36866943 | ||
| Novel Abeta immunogens: is shorter better? | Q36956829 | ||
| Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. | Q36983588 | ||
| Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice | Q37139061 | ||
| Relevance of transgenic mouse models to human Alzheimer disease | Q37307236 | ||
| The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin | Q37361308 | ||
| Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing | Q37407071 | ||
| Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. | Q37432185 | ||
| Developing novel immunogens for a safe and effective Alzheimer's disease vaccine | Q37574391 | ||
| Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease | Q37678126 | ||
| Alzheimer's disease: old problem, new views from transgenic and viral models | Q37717821 | ||
| Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. | Q39232807 | ||
| Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice | Q39843065 | ||
| Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. | Q40328434 | ||
| Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice | Q40389829 | ||
| An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. | Q40535875 | ||
| Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development | Q40597257 | ||
| Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease | Q40598120 | ||
| The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis | Q41152552 | ||
| Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. | Q42495065 | ||
| Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide | Q42610772 | ||
| Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. | Q43941772 | ||
| Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome | Q45007178 | ||
| Human monoclonal antibodies against amyloid-beta from healthy adults | Q45263093 | ||
| Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide | Q45295828 | ||
| Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities | Q45310539 | ||
| Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. | Q46733868 | ||
| Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome | Q46751023 | ||
| Anti-idiotypic antibody mimics proteolytic function of parent antigen. | Q46895023 | ||
| A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease | Q47583762 | ||
| Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model | Q48251811 | ||
| Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease | Q48300537 | ||
| Abeta species removal after abeta42 immunization | Q48378187 | ||
| Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta | Q48463395 | ||
| Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide | Q48503026 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| immunization | Q1415366 | ||
| P304 | page(s) | 409-422 | |
| P577 | publication date | 2010-05-20 | |
| P1433 | published in | Neurobiology of Disease | Q15716606 |
| P1476 | title | Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease | |
| P478 | volume | 39 |
| Q34175938 | A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy |
| Q27322890 | A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle |
| Q37435886 | Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease |
| Q39437881 | Amyloid beta: structure, biology and structure-based therapeutic development |
| Q47434009 | Glial Draper Rescues Aβ Toxicity in a Drosophila Model of Alzheimer's Disease |
| Q37984574 | Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. |
Search more.